Revvity/$RVTY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
- Ticker
- $RVTY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 11,000
- Headquarters
- Waltham, United States
- Website
- www.revvity.com
Revvity Metrics
BasicAdvanced
$17B
67.09
$2.26
1.09
$0.28
0.18%
Price and volume
Market cap
$17B
Beta
1.09
52-week high
$171.74
52-week low
$81.22
Average daily volume
1.7M
Dividend rate
$0.28
Financial strength
Current ratio
2.654
Quick ratio
1.825
Long term debt to equity
0.38
Total debt to equity
0.38
Dividend payout ratio (TTM)
12.41%
Interest coverage (TTM)
5.23%
Profitability
EBITDA (TTM)
894.062
Gross margin (TTM)
55.91%
Net profit margin (TTM)
8.61%
Operating margin (TTM)
16.66%
Effective tax rate (TTM)
10.61%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
2.59%
Return on equity (TTM)
3.45%
Valuation
Price to earnings (TTM)
67.092
Price to revenue (TTM)
5.775
Price to book
2.33
Price to tangible book (TTM)
-11.65
Price to free cash flow (TTM)
28.763
Free cash flow yield (TTM)
3.48%
Free cash flow per share (TTM)
5.27
Dividend yield (TTM)
0.18%
Forward dividend yield
0.18%
Growth
Revenue change (TTM)
4.56%
Earnings per share change (TTM)
13.45%
3-year revenue growth (CAGR)
1.71%
10-year revenue growth (CAGR)
3.94%
3-year earnings per share growth (CAGR)
-27.45%
10-year earnings per share growth (CAGR)
0.51%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Analyst projections of the future price of Revvity stock.
Bulls say / Bears say
Revvity lifted its 2026 organic-growth outlook to about 5% and its adjusted EPS range to $5.40–$5.45 after a strong third quarter. It also raised its margin outlook for the third time this year, pointing to improving demand and cost savings. (Investing.com)
AI-led drug discovery could create fresh demand for Revvity’s lab tools: management reported rising AI-related orders and an instrument backlog above normal, with demand for high-content screening outpacing near-term production capacity. (The Motley Fool)
Life Sciences remained weak in Q2, with organic revenue down 3%; Signals software fell about 20% as contract timing and tough comparisons weighed on the segment. A slow software recovery could offset growth elsewhere. (Reuters)
Some recent profit gains may not be repeatable: Q2 adjusted EPS included about $0.11 from tariff refunds, and management said some Q3 timing benefits would not recur in Q4. That makes the underlying pace of earnings improvement less clear. (Revvity, Investing.com)
The shares trade near their 52-week high and at a reported P/E of about 72.5, leaving little room for missed targets or a slower recovery in pharma and biotech spending. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Upcoming events
Revvity News
AllArticlesVideos
Funds containing Revvity
AllUSDEURGBP
Fund name | Fund size | $RVTY weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.6B | 1.73% |
iShares Healthcare Innovation£DRDR | $1.6B | 1.73% |
iShares Healthcare Innovation€2B78 | $1.6B | 1.73% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.30% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


